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Porphobilinogen synthase (PBGS) catalyzes the con-
densation of two molecules of 5-aminolevulinic acid
(ALA), an essential step in tetrapyrrole biosynthesis.
4-Oxosebacic acid (4-OSA) and 4,7-dioxosebacic acid
(4,7-DOSA) are bisubstrate reaction intermediate ana-
logs for PBGS. We show that 4-OSA is an active site-
directed irreversible inhibitor for Escherichia coli
PBGS, whereas human, pea, Pseudomonas aeruginosa,
and Bradyrhizobium japonicum PBGS are insensitive to
inhibition by 4-OSA. Some variants of human PBGS (en-
gineered to resemble E. coli PBGS) have increased sen-
sitivity to inactivation by 4-OSA, suggesting a structural
basis for the specificity. The specificity of 4-OSA as a
PBGS inhibitor is significantly narrower than that of
4,7-DOSA. Comparison of the crystal structures for E.
coli PBGS inactivated by 4-OSA versus 4,7-DOSA shows
significant variation in the half of the inhibitor that
mimics the second substrate molecule (A-side ALA).
Compensatory changes occur in the structure of the
active site lid, which suggests that similar changes nor-
mally occur to accommodate numerous hybridization
changes that must occur at C3 of A-side ALA during the
PBGS-catalyzed reaction. A comparison of these with
other PBGS structures identifies highly conserved ac-
tive site water molecules, which are isolated from bulk
solvent and implicated as proton acceptors in the PBGS-
catalyzed reaction.
Porphobilinogen synthase (PBGS,1 EC 4.2.1.24, also known
as 5-aminolevulinate dehydratase) recently has emerged as a
viable enzyme target for the development of pharmaceuticals
or agricultural agents. The PBGS protein, which is highly
conserved in both sequence and structure (1), catalyzes an
early essential step in the biosynthesis of the tetrapyrrole
cofactors such as heme and chlorophyll (Fig. 1A). Despite the
fact that much is known about the PBGS structure, the se-
quence of bond-making and bond-breaking events that follow
formation of the ternary complex of PBGS with the two sub-
strate molecules is the subject of active discussion (2–5). Based
on an extensive phylogenetic variation in the number and
kinds of metal ions used for catalytic and/or allosteric roles, it
is possible that the order of chemical events in the enzyme-
catalyzed reaction mechanism may not be phylogenetically con-
served. In order to probe the mechanism, 4,7-dioxosebacic acid
(4,7-DOSA) and 4-oxosebacic acid (4-OSA), illustrated in Fig.
1B, were designed and found to act as suicide substrates for
Escherichia coli PBGS (6). These inhibitors mimic an addition
product intermediate in which the first bond formed between
the two 5-aminolevulinic acid (ALA) substrate molecules cre-
ates a carbinolamine that dehydrates to a Schiff base (6). More
recently, a strong species-selective inhibition of PBGS by 4,7-
DOSA has been correlated with an active site variation in
metal ion usage (3). Here we have characterized a very differ-
ent species selectivity for 4-OSA inhibition of PBGS and pro-
vide a 1.9-Å crystal structure of 4-OSA-inhibited E. coli PBGS.
This structure was compared with an improved 1.7-Å crystal
structure of E. coli PBGS inhibited by 4,7-DOSA and with
analogous structures of these inhibitors bound to yeast PBGS
(for which, however, there are no kinetic inhibition data) (5).
EXPERIMENTAL PROCEDURES
Materials—Most chemicals and buffers were obtained from Fisher or
Sigma in the purest available form. 2-Mercaptoethanol (ME) from
Fluka (Buchs, Switzerland) was vacuum-distilled prior to use. 4-OSA
and 4,7-DOSA were synthesized and tested (as described in Ref. 6). All
of the PBGS enzymes used in this study were cloned and expressed in
E. coli, and purification and detailed characterization has been de-
scribed previously (7–12). Human PBGS was the C162A variant of the
natural N59 isozyme, and it has kinetic properties closely resembling
the wild type (13). Human PBGS mutants characterized with 4-OSA
were N59/C162A/H131A/C223A (called MinusZnA) (13) and two new
chimeric proteins (HsALK and HsEclid) containing portions of the E.
coli PBGS active site lid. The chimeric proteins were prepared from the
plasmid encoding wild type human PBGS variant N59/C162A by the
QuikChange method of mutagenesis. The sense strand primers were
CCGTTCCGTGATGCGCTAAGTCAGCATTAAAAGGCGACCGCCGC-
TGC for HsALK and CCGTTCCGTGAAGCTGCTGGGTCAGCCTTA-
AAAGGCGACCGCAAAGCTATCAG for HsEclid.
Activity Assays for PBGS—The enzyme assay measures the forma-
tion of porphobilinogen from ALA. The assay conditions at optimal pH
and with a full complement of required and allosteric metal ions in the
standard 5-min assay procedure for each of the five PBGS were per-
formed as described previously (3). Human mutants MinusZnA,
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HsALK, and HsEclid were assayed in the same fashion as the wild
type. To ensure reliable A555 values, assays of low specific activity
mutants used a 30-min incubation with substrate. Enzyme concentra-
tions were measured with Coomassie Plus protein assay reagent
(Pierce) relative to a standard curve prepared with bovine serum
albumin.
Inhibition of PBGS by 4-OSA—The five species of PBGS (1 M
subunit) were preincubated under optimal assay conditions for 10 min
at 37 °C prior to the addition of 4-OSA over the concentration range of
10 M to 3 mM; preincubation was allowed to proceed for various times
ranging from 90 min to 22 h at 37 °C before initiating the formation of
porphobilinogen by addition of ALA-HCl to a final concentration of 10
mM. Porphobilinogen formation was allowed to proceed for 5 min. For E.
coli PBGS, 4-OSA inhibition data were fitted to the equation v/vo 
1/(1([I]/IC50)) (14) using the program SigmaPlot (SPSS, Chicago, IL).
For other species of PBGS the apparent IC50 values for 4-OSA were well
above millimolar concentrations and the 10 M–3 mM inhibition data
could not be fit well. In these cases a simple direct comparison of the five
species used a 4-OSA concentration of 3 mM and a 24-h enzyme/inhib-
itor incubation time prior to the addition of ALA.
Crystallization of E. coli PBGS Complexed with 4,7-DOSA and
4-OSA and Structure Solution—Crystallizations were carried out with
both 4-OSA and 4,7-DOSA as described previously for 4,7-DOSA (3). In
both cases, E. coli PBGS (9 mg ml1 in 50 mM Tris-HCl, pH 8.0, 10 mM
ME, 20 M ZnCl2, 10 mM MgCl2) was incubated for 24 h at 37 °C with
a 16-fold molar excess of the inhibitor (4 mM) prior to setting up the
crystallization trays. An equal volume of clarified protein was mixed
with reservoir buffer containing 1–6% polyethylene glycol 3350, 10%
glycerol, 0.1 M Tris-HCl, pH 8.5, and 0.02% sodium azide. The crystals
with a diamond-like shape appeared in 1–3 days, and the largest
crystals grew to their final size (up to 0.6  0.6  0.3 mm3) in approx-
imately 2 weeks. Cryoprotection was carried out by transferring a
crystal to reservoir solutions containing 17, 23, and 30% glycerol, re-
spectively (3 min in each solution), and the crystal was flash-frozen in
a liquid nitrogen vapor. X-ray diffraction data for both complexes were
collected from one crystal at 100 K using a QUANTUM-4 CCD detector
mounted at synchrotron beamline X9B at Brookhaven National Syn-
chrotron Light Source facility. The data sets consisted of 180 frames
chosen to cover at least one asymmetric unit with each frame corre-
sponding to 0.5° oscillation exposed for 35 s. Crystals belong to a
tetragonal system, space group, P4212; unit cell parameters, a  b 
129.0 Å, and c  142.8 Å with two molecules per asymmetric unit.
Diffraction intensities were processed with the HKL2000 suite of pro-
grams (15), resulting in final data sets with Rmerge(I)  5.1 and 5.6% for
126,253 and 92,714 independent reflections and with completeness of
95.7 and 99.8% for the 40–1.7 and 40–1.9 Å resolution range for
4,7-DOSA and 4-OSA complexes, respectively.
Because the crystals were in both cases isomorphous to that of E. coli
PBGS complexed with 4,7-DOSA (PDB entry 1I8J), rigid body refine-
ment of the PBGS dimer against the corresponding diffraction data was
sufficient to properly orient the protein model in the respective crystal
unit cell. Refinement was carried out with program package CNS (16)
with weak non-crystallographic symmetry restraints corresponding to
weight 25. Model building was performed with program O (17). The
final models included one dimer of PBGS molecule complexed with two
respective inhibitor molecules, 498 and 433 water molecules for 4,7-
DOSA and 4-OSA, respectively, as well as two Zn2 and two Mg2 ions.
Five glycerol molecules were found in the 4-OSA structure. The crys-
tallographic R-factors were 19.5 and 20.6%, R(free) parameters were 24.3
and 26.3% for the 1.7- and 1.9-Å resolution data, and the RMS devia-
tions for bond lengths and bond angles were 0.018 Å and 1.8° for
4,7-DOSA and 0.019 Å and 2.0° for 4-OSA, respectively. The coordinates
have been deposited in the Protein Data Bank with the PDB codes 1L6S
and 1L6Y for immediate release.
RESULTS
Kinetic Evaluation of the Inhibition of PBGS Enzymes by
4-OSA—The inactivation of PBGS by 4,7-DOSA was shown
previously to be dependent both upon the concentration of the
inhibitor and the preincubation time of the inhibitor and en-
zyme prior to addition of substrate (3). This is also true for
4-OSA, which was a less potent inactivator than 4,7-DOSA.
Fig. 2A illustrates the time and concentration dependence for
the interaction of 4-OSA with E. coli PBGS using enzyme/
inhibitor incubation times of 94 min and 16 h and 4-OSA
concentrations from 10 M to 3 mM. For comparison we also
included data from a comparable 100-min incubation of E. coli
PBGS in which 4,7-DOSA was the inhibitor (3). These data
indicate that 4-OSA is far less potent against E. coli PBGS than
is 4,7-DOSA, consistent with prior reports (6). Using the ap-
proximation of Copeland et al. (14), the IC50 values for E. coli
PBGS inhibition by 4-OSA at 94 min and 16 h are 0.57  0.06
mM and 0.22 0.01 mM, respectively. The IC50 for 4,7-DOSA at
100 min of incubation with E. coli PBGS is 0.039  0.002 mM.
The reduced sensitivity to 4-OSA relative to 4,7-DOSA is also
true for human, Bradyrhizobium japonicum, Pseudomonas
aeruginosa, and Pisum sativum (pea) PBGS, where a similar
experiment showed marginal if any inactivation by 4-OSA
across the range of 10 M to 3 mM 4-OSA. To compare the five
species, Fig. 2B illustrates a 24-h preincubation of 3 mM 4-OSA
with all five PBGS and shows a high selectivity for inactivation
of E. coli PBGS. The control reactions wherein inhibitor was
omitted did not lose any significant activity.
Evaluation of 4-OSA with Mutant Forms of Human PBGS—
The high selectivity of 4-OSA inactivation for E. coli PBGS is in
sharp contrast to the species selectivity of inactivation by 4,7-
DOSA (3). The latter showed a marked preference for the
Zn2-utilizing PBGS and was highly effective against human
PBGS, which contains two different types of Zn2 binding sites.
In that case, evaluation of an active human PBGS mutant
(MinusZnA) that lacked the nonessential Zn2 showed reduced
sensitivity to 4,7-DOSA. Of the five species evaluated, only
human and E. coli PBGS use a catalytic Zn2. Because the
number and types of Zn2 sites are a significantly different
between human and E. coli PBGS, this MinusZnA human
PBGS was also evaluated with 4-OSA, and the results are
included in Fig. 2C. Consistent with the notion that MinusZnA
is more like E. coli PBGS, MinusZnA retains only 65% activ-
ity after a 22-h incubation with 3 mM 4-OSA. Thus, MinusZnA
is significantly more sensitive to inactivation by 4-OSA than is
FIG. 1. PBGS-catalyzed reaction and bisubstrate/intermediate
site-directed inhibitors. A, PBGS catalyzes the first common step in
the biosynthesis of the tetrapyrroles. The chemistry is an asymmetric
condensation of two molecules of ALA. A-side ALA contributes the
acetyl side chain and retains a free amino group. P-side ALA (bold
bonds, italic) contributes the propionyl side chain and has its amino
group incorporated into the pyrrole ring. B, the PBGS inhibitors 4,7-
DOSA and 4-OSA both mimic a putative reaction intermediate wherein
C4 of A-side ALA forms a Schiff base with the C5 amino group derived
from P-side ALA.
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human PBGS, but it remains far less sensitive than E. coli
PBGS.
In search for the structural basis for the high selectivity of
4-OSA against E. coli PBGS, we compared the known struc-
tures (and sequences) of the PBGS to define unique features of
E. coli PBGS. One significant variable feature in the PBGS
family of proteins is the length and sequence of the active site
lid. Based on the E. coli PBGS crystal structure, the lid is
defined as the stretch from Ala196 to Gln219. The lid includes all
of the residues in this region that are found to be disordered in
PBGS structures 1AW5, 1B4K, and 1E51. Fig. 3A shows a
structure-based sequence alignment of the active site lid of
human, yeast, E. coli, P. aeruginosa, B. japonicum, and P.
sativum PBGS, which is different from previously published
sequence-based alignments. Fig. 3B shows a color-coded struc-
tural overlay of the lid region from PBGS corresponding to PDB
codes 1E51 (human), 1YLV (yeast), 1I8J (E. coli), and 1B4K (P.
aeruginosa). E. coli PBGS is unique among those tested with
4-OSA in that it has the shortest lid sequence. To evaluate the
significance of this variable, we created, prepared, and charac-
terized two chimeric “lid-switch” PBGS based on human PBGS
using portions of the E. coli lid sequence.
The minimal lid switch chimeric protein contains the small
portion of the E. coli lid that varies in backbone structure. The
sequence of this variant, called HsALK, is included in Fig. 3A.
HsALK is an active PBGS with a specific activity of 4% of
wild type human PBGS and a normal Km value. Purified
HsALK contains 3.5 Zn2/octamer. As predicted from its in-
creased sequence similarity with E. coli PBGS, HsALK has
increased sensitivity to inhibition by 4-OSA (see Fig. 2C). A less
predictable result was observed when a larger portion of the lid
sequence was switched. The human PBGS variant HsEclid
contains the E. coli PBGS lid sequence from Arg204 to Gln219 (E.
coli numbering) as illustrated in Fig. 3A. HsEclid is also an
active PBGS with a specific activity of 12% of wild type
human PBGS and a normal Km value. HsEclid was found to
purify with 4.5 Zn2/octamer. Inconsistent with other human
PBGS variants that are designed to resemble E. coli PBGS,
HsEclid is insensitive to inhibition by 4-OSA (see Fig. 2C). The
human PBGS variant MinusZnA, whose behavior with 4-OSA
is described above, is included in Fig. 3 because one of the
mutations (C223A) is in this active site lid region. The Zn2
stoichiometry of HsALK and HsEclid suggests that these
human PBGS variants retain the property of half-site reactiv-
ity, a kinetic property that is well established for human PBGS
but not for E. coli PBGS.
E. coli PBGS Crystal Structures with 4-OSA and 4,7-
DOSA—The PBGS all share a common octameric structure
with two monomers forming a dimer around either the non-
crystallographic or crystallographic 2-fold symmetry axis and
four such dimers forming a PBGS octamer around the 4-fold
symmetry axis. Each monomer/subunit forms an -barrel, the
center of which holds the active site residues, while an N-
terminal arm that varies in length between species is mutually
wrapped around the neighboring subunit forming a compact
dimeric structure. The N-terminal arms are involved in exten-
sive subunit interactions within and between dimers. Some
PBGS crystal structures show an individual subunit as the
asymmetric crystallographic unit, and others (such as those
presented here) show a dimer as the asymmetric unit. A variety
of data have been interpreted to indicate that an oligomeric
structure is required for activity (see Ref. 7). Each active site
region is confined to one subunit and isolated from bulk solvent
by a lid. The 4,7-DOSA-containing E. coli PBGS was the first
structure to show that the lid-closed configuration involves
extensive hydrogen bonding with the carboxyl group of the
A-side ALA molecule, which makes up the acetyl half of por-
phobilinogen (see Fig. 1A and below) (3). The structure is
consistent with the notion that P-side ALA, which makes up
the propionyl half of the product, binds first and that the A-side
ALA binds second (see Refs. 18 and 19). Similar to other -
FIG. 2. Inactivation of PBGS by 4-OSA. A, inactivation of E. coli
PBGS by 4-OSA (circles) relative to previously published data for 4,7-
DOSA (squares) (3). Enzyme incubation times (prior to addition of
substrate) are 94–100 min for the filled symbols and 16 h for the open
symbols. Lines are best fit to the equation v/vo  1/[1([I]/IC50)] (14). B,
inactivation of a family of wild type PBGS enzymes by 3 mM 4-OSA
using a fixed 24-h inhibitor/enzyme incubation time prior to activity
assay. The species are E. coli (Ec), human (Hs), B. japonicum (Bj), P.
aeruginosa (Pa), and P. sativum L. (Ps). For these determinations, the
protein concentrations were all at 1 M subunit. C, inactivation of
mutant or chimeric PBGS by 3 mM 4-OSA using a 24-h enzyme/inhib-
itor incubation time. The bars correspond to E. coli (Ec), human (Hs),
human MinusZnA (ZnA), HsALK, and HsEclid.
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barrel enzymes, the ordering and disordering of the active site
lid appears to be essential for substrate binding, isolation of the
active site from bulk solvent, and product release. The current
structures better define these lid motions. The lid residues seen
to interact with active site ligands presented here and else-
where are denoted in Fig. 3.
Here we present the crystal structures of E. coli PBGS that
has been inactivated by 4-OSA and of another one that has
been inactivated by 4,7-DOSA. The latter structure is the same
complex that we already published (PDB code 1I8J); however,
this time resolution of the diffraction data was extended to 1.7
Å so that we were able to locate 183 extra water molecules,
clarify that both Cys133A and Cys133B are adducted with -mer-
captoethanol (see below), and generally provide a more accu-
rate structural description of the protein and the inhibitors. A
major new observation based on this structure is a significant
variation in the position of the inhibitor half that mimics A-side
ALA. Such a result has not been reported for the comparable
complex of 4-OSA with yeast PBGS (5). Similar to the complex
of 4,7-DOSA-inhibited PBGS, the 4-OSA-inhibited E. coli
PBGS asymmetric unit contains a dimer, and each subunit of
the 4-OSA complex contains one inhibitor molecule, one Zn2
bound at the active site, and one Mg2 bound at the allosteric
site (Fig. 4). Unlike the 4,7-DOSA-inhibited PBGS, the 4-OSA
complex can form only one Schiff base linkage between each
inhibitor and PBGS subunit; this linkage is observed. The RMS
deviation between the C atoms of the two monomers forming
a non-crystallographic dimer is 0.25 Å, whereas the RMS de-
viation between the 4,7-DOSA- and 4-OSA-inhibited PBGS
dimers is 0.24 Å. Thus, we conclude that there are no signifi-
cant differences between the monomers of the dimer or the
dimers themselves upon binding either to 4,7-DOSA or 4-OSA
(except for part of the lid near Arg204, described below), al-
though the conformations of some side chains (mainly those
located on the surface of the octamer) are occasionally different.
The average temperature factors are 43.2 and 43.4 Å2 for
monomers A and B of the 4-OSA-containing complex and 30.2
and 31.2 Å2 for monomers A and B of the 4,7-DOSA-containing
complex. This indicates that the monomers in each complex
have essentially the same degree of flexibility, although the
crystals of the 4,7-DOSA complex have better internal order.
The symmetry seen in E. coli PBGS dimers is in sharp contrast
to the high resolution asymmetric dimer seen in P. aeruginosa
PBGS (PDB code 1B4K) (20) and the less well resolved human
PBGS, which contains extensive disorder (PDB code 1E51,
unpublished structure).
The two E. coli PBGS structures presented here clarify the
amino acid identity of position 133, which had previously been
identified as a lysine (2). The DNA sequence indicates Cys133 and
mass spectroscopy analysis of an AspN digest was obtained
herein to demonstrate the existence of a cysteine in this position.
Because Cys133 is located on the surface of the protein, which has
been purified and stored in the presence of mercaptoethanol, this
residue appears as an adduct of ME and cysteine (S,S-2-(hy-
droxyethyl)thiocysteine). The adduct was first reported in a V23C
variant of staphylococcal nuclease (21), and the current electron
density is an excellent fit to this model.
Mechanism of Inhibition by 4-OSA and 4,7-DOSA—The in-
hibitor molecules are clearly seen in the difference electron
density maps in the area of the active site next to Lys194 and
Lys246 in both monomers. In the case of 4,7-DOSA there are
two covalent linkages between the protein and the inhibitor,
and in the case of 4-OSA there is one covalent linkage. Fig. 5A
illustrates an electron density map of 4-OSA bound to the
enzyme, and Fig. 5B shows a comparison between the 4-OSA-
and 4,7-DOSA-inhibited proteins. In both cases C1-C5 of the
FIG. 3. Variations in the PBGS active site lid. A, structure-based sequence alignment of PBGS from human, yeast, E. coli, P. aeruginosa, B.
japonicum, and P. sativum L. showing only the active site lid. Sequences are included for the variant and chimeric human PBGS that were
evaluated as targets for 4-OSA inhibition. The region containing the R(X)10–13 R/K(X3)Q sequence forms multiple H-bonding interactions with the
carboxyl group derived from A-side ALA. The gray background corresponds to the region of variable sequence length. Sequences in bold are
included in and color-coded to the structure alignment in B. Amino acids seen to interact with active site ligands are denoted with an asterisk. B,
a stereo view structure alignment showing the closed-lid conformation of human (black), yeast (red), E. coli (green), and P. aeruginosa (yellow)
PBGS for the sequence region shown in A.
FIG. 4. A stereo diagram of the 4-OSA inactivated E. coli PBGS
dimer. The two monomers are shown in blue and magenta, Zn2 is dark
green, Mg2 is orange, and the active site lid is yellow. The two active
site lysine residues are shown (ball-and-stick) with bonds colored ac-
cording to the subunit; Lys246 makes Schiff base to atom C4 of the
inhibitor. The 4-OSA molecules are shown (ball-and-stick) with bonds
in green. Atom color code is C, green; N, blue; O, red.
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inhibitor are bound with a Schiff base linkage between C4 and
the -amino group of Lys246. In these cases, as well as in related
PBGS structures with inhibitors bound in the P-side ALA bind-
ing pocket (PDB codes: 1B4E, 1B4K, 1EB3, 1YLV, 1I8J, 1GJP,
1H7N, 1H7P, 1H7R), the C1 carboxyl oxygens of the inhibitor
make hydrogen bonds with Ser272 and Tyr311. The positions of
the C2 and C3 atoms of each inhibitor are well defined but not
equivalent to each other. The variation in these positions mim-
ics the reported alternate conformations of levulinic acid bound
as the P-side Schiff base to yeast PBGS (PDB code 1H7N) (22).
This variation defines the limited spatial flexibility of P-side
ALA and dictates that these atoms cannot reorient much in
response to required hybridization changes at C4. The position
of C1-C4 of 4-OSA more closely resembles that of the product
porphobilinogen. As reported previously for the 1.9-Å structure
of 4,7-DOSA-inhibited E. coli PBGS, the bond between C5 and
C6 of the inhibitor has a distorted cis-configuration (torsion
angle of C4–C5–C6–C7 is 65°) to accommodate a second
Schiff base linkage between C7 and the -amino group of
Lys194. Because there is no Schiff base to Lys194 in the 4-OSA-
inhibited enzyme, the conformation around the C5–C6 bond
(torsion angle C4–C5–C6–C7 is 88°) and the positions of
C5-C10 of reacted 4-OSA are significantly different from those
seen for 4,7-DOSA (Fig. 5B). This suggests that A-side ALA has
much greater positional flexibility than does P-side ALA. Posi-
tional flexibility is essential to accommodate the multiple hy-
bridization changes required in the formation of porphobilino-
gen. In the case of both inhibitors, the A-side ALA half (C8–
C10) extends out toward the lid where it makes extensive
hydrogen-bond linkages between the C10 carboxyl oxygens and
arginine residue(s). However, the hydrogen-bonding pattern is
not the same for the two inhibitors, as illustrated schematically
in Fig. 6. Unlike 4,7-DOSA, 4-OSA does not interact with
Gln219 through hydrogen bonds directly; instead it does so
through a bridging water molecule. This is the same water
molecule that forms similar bridging hydrogen bonds between
Gln219 and Arg204 in the 4,7-DOSA-containing complex. To
accommodate the different structure of the A-side half of the
4-OSA inhibitor, the side chain of Arg204 moves approximately
2.5 Å away from the position it occupied in the 4,7-DOSA
complex (Fig. 5B) and is locked in this new position by a
hydrogen bond between its side chain NH1 atom and the car-
bonyl oxygen of Gly213. The position of Arg204 in the absence of
an A-side ligand (structure 1B4E) is much like that of the
4,7-DOSA-containing complex, but its H-bonds are strictly to
water. Despite the different position of the Arg204 side chain in
FIG. 5. The active sites of 4-OSA and 4,7-DOSA inactivated E. coli PBGS. A, stereo picture of the electron density corresponding to 4-OSA,
Lys194, and Lys246 at the active site of the enzyme. Atoms derived from 4-OSA are in magenta; atoms of Lys194 and Lys246 are black; carbons from
protein are green; nitrogen is blue; oxygen is red; sulfur is yellow; and Zn2 is black. Highly conserved active site water molecules are included. The
illustration shows a 2Fo  Fc difference electron density map contoured at a level of 1.5. B, stereo overlay of 4,7-DOSA (blue)-inhibited E. coli
PBGS (black) with 4-OSA (magenta)-inhibited E. coli PBGS (green).
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these structures, the C atoms of this part of the lid (positions
203–205) move 1.4 Å. The difference in the position and
conformation of the A-side of 4-OSA results in C7 being approx-
imately 1 Å closer to the catalytic Zn2; the distance C7-Zn2 is
4.5 versus 5.5 Å in 4,7-DOSA. There are several ordered water
molecules found within a 5-Å distance from the inhibitor in the
A-side of both complexes that are included in Fig. 5. They are
all the same in both structures and are also seen in high
resolution structures of yeast PBGS and P. aeruginosa PBGS.
DISCUSSION
4-OSA Bound to PBGS—The structures presented in Fig. 5B
can be compared with recently published crystal structures of
these inhibitors with yeast PBGS (PDB codes 1EB3 and 1GJP)
(5). In these structures the A-side of the inhibitor is modeled
such that the carboxyl groups of 4-OSA and 4,7-DOSA are in
nearly the same position as each other. In the case of 4-OSA, we
consider this interpretation questionable because Arg220 (the
counterpart of E. coli Arg204) is shifted 2.6 Å away from the
active site in a manner similar to what is found in the E. coli
4-OSA-inhibited PBGS structure. In the yeast structure, the
dramatically shifted Arg220 does not interact with the inhibitor
or any other atoms except for two water molecules on the
surface of the protein. In fact, 4-OSA of 1GJP is reported as
“somewhat disordered,” and the presented electron density
map is completely lacking density for one of the A-site carboxyl
oxygens. A more compelling reason to question the model for
4-OSA bound to yeast PBGS comes from a comparison of the
yeast PBGS structure IGJP with the E. coli PBGS complex
presented here. When one superimposes the 4-OSA-inhibited
E. coli PBGS structure (where inhibitor was perfectly ordered)
with 1GJP (superposition was based only on the protein parts
of the complex), we find that our 4-OSA inhibitor makes exactly
the same hydrogen bonds with the yeast enzyme, including
Arg220 in its new position, as in E. coli 4-OSA PBGS complex.
In other words, the structure of 4-OSA as it is found in the
complex with E. coli PBGS is energetically more favorable upon
binding to the yeast enzyme than the one that was reported in
the crystal structure of the complex of 4-OSA with yeast PBGS
itself (5). Taken together, these points shed doubt on the inter-
pretation of the conformation of 4-OSA bound to yeast PBGS in
structure 1GJP.
The PBGS-catalyzed Reaction Mechanism, Active Site Lid
Motion, and Enzyme-bound Active Site Water—The PBGS-cat-
alyzed reaction is illustrated in Fig. 1. The first ALA to bind to
PBGS is P-side ALA (18). P-side ALA forms a Schiff base
intermediate to an active site lysine (Lys246 in E. coli PBGS)
(23). Metals are not required for the binding or reactivity of
P-side ALA (19). Maintenance of the deprotonated Schiff base-
forming lysine is accomplished by the neighboring basic resi-
due (here Lys194). As with all Schiff base-forming enzymes, one
expects to be able to identify the residue that serves in the
removal of the oxygen atom from the carbinolamine interme-
diate that precedes P-side Schiff base formation. This residue is
not apparent in any PBGS crystal structures and has not been
addressed in prior publications. The existing PBGS structures
all place the P-side Schiff base in a very hydrophobic environ-
ment, part of which is composed of aromatic residues in the
N-terminal portion of the active site lid (see Fig. 5). Because
this Schiff base occurs for both 4-OSA and 4,7-DOSA, and the
resulting water molecule is not observed near the P-side of the
inhibitor, we conclude that this first water molecule must re-
locate prior to lid closure. One possible acceptor for the carbi-
nolamine hydroxyl group would be the protonated Lys194 in a
rotomer conformation different from that which is observed in
here. In this case the reaction would be as shown in Reaction I.
R2CAONH2–Lys246 NH3
–Lys194¡
OH

R2C–NH–Lys246 NH3
–Lys194¡
R2CANH–Lys246H2ONH2–Lys194
REACTION I
FIG. 6. Schematic diagram of the hydrogen bonding of 4-OSA (A) and 4,7-DOSA (B) with E. coli PBGS. The carbon atoms of 4-OSA and
4,7-DOSA are numbered. Water molecules are represented by single oxygen atoms as O. Dashed lines indicate potential hydrogen bonds using a
heteroatom distance of 3.2 Å. Hydrogen bonds are depicted for subunits A. In subunit B the Gly213(O)-Arg204(N), the 4-OSA(O)–Arg204(NE), and
the 4-OSA(O)–water(connected to Gln219) distances are 3.5–3.8 Å. Dotted lines indicate the Zn2 ligand bonds, which are each 2.4 Å.
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Alternatively, one may propose that the protonated base that
dehydrates the P-side carbinolamine comes from an alternate
configuration of the active site lid. The lid contains many con-
served basic residues (see Fig. 3), which (as seen in the struc-
tures presented here) can interact with the A-side carboxyl
group later in the reaction but may serve an additional function
earlier.
The second ALA to bind to PBGS is A-side ALA. For those
PBGS that use a catalytic Zn2, the metal ion is required for
A-side ALA binding and reactivity (19). The crystal structures
of 4,7-DOSA- and 4-OSA-inhibited PBGS support the mecha-
nistic hypothesis that the keto oxygen removed from C4 of
A-side ALA (C7 of the inhibitors) ends up coordinated to the
catalytic Zn2 (3). We have proposed that A-side ALA binds as
a bidentate Zn2 ligand through the C4 keto oxygen and the C5
amino group (24). Molecular modeling studies indicate that
this complex fits into the A-side ALA binding pocket and takes
advantage of the unique flexibility of Zn2 to accommodate
various coordination numbers and geometries (25). The coordi-
nation environment of this Zn2 is unusual for a catalytic Zn2
in that it contains three cysteine ligands that derive from a
short stretch of 11 amino acids. The structures presented here
indicate that the Zn2-bound water molecule is appropriately
positioned to have derived from the keto group analogous to
that of A-side ALA.
Based on the extensive hydrogen-bonding interactions be-
tween the A-side carboxylic acid group of 4-OSA and 4,7-DOSA
and the active site lid residues, we conclude that A-side ALA
binding necessitates the ordering or reordering of the active
site lid. Comparison of the conformation of the lid between the
4,7-DOSA, 4-OSA, and 1B4E (the complex of E. coli PBGS and
levulinic acid) structures shows that most of the conforma-
tional change upon inhibitor binding occurs in the part of the
lid between positions 200 and 205. The deviation of the C
atoms in this region does not exceed 1.4 Å, the side chain of
Arg204 is shifted approximately 2.5 Å away from the active site
to accommodate the A-side part of 4-OSA, and the other side
chains occupy very much the same positions in all three
complexes.
The PBGS-catalyzed reaction involves significant hybridiza-
tion changes at multiple carbon centers (see Fig. 1). As de-
scribed above, large translational motion is not possible for the
propionyl side chain of P-side ALA. For A-side ALA, the C5
amino-containing portion appears relatively fixed through in-
teraction with the catalytic Zn2. This is apparent from prior
13C and 15N NMR data (26) and from the observation that the
amino group of the product porphobilinogen is chelated to the
Zn2 in the unpublished human PBGS structure 1E51 and in
the complex of E. coli PBGS with porphobilinogen.2 Thus, to
accommodate the significant hybridization changes, particu-
larly at C3 of A-side ALA, the acetyl side chain must experience
substantial mobility throughout the course of the reaction. One
significant contribution of the current structure is the visual-
ization of a different orientation for the inhibitor atoms C6–
C10 analogous to C1–C5 of the A-side ALA. We propose that
the observed multiple hydrogen bonds between the C10 car-
boxyl and Arg204, Arg215, Gln219, and associated water mole-
cules change conformation to accommodate various positions of
C1 and C2 of A-side ALA during the course of the PBGS-
catalyzed reaction.
A particularly vexing question in understanding the PBGS-
catalyzed reaction mechanism has been the identification of the
residues that serve as acceptors for the four protons and two
oxygen atoms lost in the condensation of two ALA molecules to
porphobilinogen. The contribution of these crystal structures to
identifying the oxygen acceptors is discussed above. The proton
acceptor(s) for the deprotonations of the amino group and C5 of
P-side ALA appear to be the two active site lysine residues as
discussed previously (2). Remarkably, there are no amino acids
positioned to be the proton acceptors at A-side ALA. Rather,
comparison of these and other PBGS structures shows a bath of
highly conserved water molecules adjacent to and including the
Zn2-bound water that initially derives from C4 of A-side ALA.
These water molecules are illustrated in Fig. 5A. Their posi-
tions are highly conserved, and they are isolated from bulk
solvent. These water molecules appear to be the only possible
acceptors for the protons that must be lost from A-side ALA.
The implication of water as the proton acceptor in the forma-
tion of an enamine from an imine, akin to the removal of the
first proton from C3 of A-side ALA, is not without precedent.
Analogous chemistry has recently been implicated in the mech-
anism of D-2-deoxyribose-5-phosphate aldolase (27).
In summary, the PBGS-catalyzed reaction mechanism has
been a subject of debate for more than three decades. In fact,
many different detailed reaction mechanisms have been illus-
trated in the literature (e.g. Refs. 2, 4–6, 18, 28–30), most of
which do not include a role for one or more essential metal ions.
Basic features such as the order of bond-making and bond-
breaking reactions in the PBGS-catalyzed reaction remains
uncertain and may not be conserved for all of the PBGS from
different species. The current structures do not resolve these
uncertainties. However, the new structures of 4-OSA- and 4,7-
DOSA-inhibited PBGS help identify the acceptor groups for the
atoms that are abstracted from the substrate molecules. They
suggest that enzyme-bound active site water molecules play
pivotal roles in the PBGS-catalyzed reaction and that there is
a mechanistic importance to fluctuations between multiple con-
formations of the active site lid.
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